Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer

Amsterdam-Duivendrecht, The Netherlands, September 29, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders, today announces the appoint­ment of Dr. Andrew Sandler as Chief Medical Officer (CMO), effec­tive October 1, 2017. Dr. Sandler will take over the role from Dr. Jeroen Rovers who will work close­ly with Dr. Sandler until the end of 2017, as part of a planned tran­si­tion.
Dr. Sandler will be a mem­ber of the Executive Management Team and will over­see the over­all med­ical func­tion and strat­e­gy of the Company, includ­ing clin­i­cal devel­op­ment, reg­u­la­to­ry affairs, phar­ma­covig­i­lance and med­ical affairs.
Dr. Sandler has over 20 years of expe­ri­ence with­in the health­care indus­try, ded­i­cat­ed to hema­to­log­ic malig­nan­cies and sol­id tumors. He has served as the senior med­ical exec­u­tive in mul­ti­ple glob­al NASDAQ list­ed oncol­o­gy com­pa­nies. Most recent­ly, Dr. Sandler was Senior Vice President, Medical Affairs, at Medivation (now part of Pfizer). Prior to that he was CMO at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-lev­el posi­tions with sev­er­al oth­er lead­ing biotech­nol­o­gy and phar­ma­ceu­ti­cal com­pa­nies, includ­ing Bayer Healthcare, Berlex and Seattle Genetics. Dr. Sandler obtained his MD from Mount Sinai School of Medicine, New York and com­plet­ed a fel­low­ship in med­ical oncol­o­gy at University of California San Francisco. A US cit­i­zen, Dr. Sandler is a board cer­ti­fied med­ical oncol­o­gist and has treat­ed many patients with hema­to­log­ic malig­nan­cies, includ­ing bone mar­row trans­plant patients.

Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “I am delight­ed to wel­come Dr. Andrew Sandler to Kiadis Pharma. Andrew’s vast expe­ri­ence and track record of guid­ing late-stage oncol­o­gy and cell ther­a­py prod­ucts through reg­is­tra­tion and launch in Europe and the US will be of immense val­ue. He will be instru­men­tal in fur­ther build­ing recog­ni­tion for and adop­tion of ATIR101™ in the med­ical com­mu­ni­ty, and allow us to cre­ate a strong pres­ence in the US.
Combined with the appoint­ment of Jan Feijen as Chief Operations Officer and for­mer Actelion COO Otto Schwarz join­ing our Supervisory Board, we now have a sea­soned lead­er­ship team of the high­est cal­iber to bring this unique orphan drug to patients.
I would like to express our grat­i­tude to Dr. Jeroen Rovers for his sig­nif­i­cant con­tri­bu­tions to Kiadis Pharma, as evi­denced by the European Marketing Authorization Application and FDA RMAT des­ig­na­tion for ATIR101™.

Andrew Sandler, com­ment­ed: “I am very excit­ed to join Kiadis Pharma at this cru­cial time in the Company’s growth. I look for­ward to guid­ing ATIR101™ through the next stages of its devel­op­ment, with the goal of bring­ing this inno­v­a­tive treat­ment to patients in Europe and the US. I have a per­son­al pas­sion for the field of oncol­o­gy and I tru­ly believe ATIR101™ can address a huge unmet med­ical need for patients under­go­ing hematopoi­et­ic stem-cell trans­plan­ta­tions.

Leave a Reply

Your email address will not be published. Required fields are marked *